Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FavLap: Favipiravir Post-Exposure Prophylaxis for Lassa Fever
jRCTs031230118Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of favipiravir in Lassa fever, sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Lassa fever incidence. Started Dec 2023; status: completed.
02
Drugs
favipiravir
03
Conditions
Lassa fever
Beyond the preview
Go deeper on jRCTs031230118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230118.